Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Trial Profile

A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Abacavir; Atazanavir; Darunavir; Delavirdine; Didanosine; Dolutegravir; Efavirenz; Elvitegravir; Emtricitabine; Lamivudine; Lopinavir; Nelfinavir; Nevirapine; Raltegravir; Rilpivirine; Saquinavir; Stavudine; Tenofovir alafenamide; Tenofovir disoproxil fumarate; Tipranavir; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BRAAVE 2020
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 27 Mar 2019 Status changed from recruiting to active, no longer recruiting.
    • 12 Dec 2018 Planned End Date changed from 1 Sep 2020 to 1 Aug 2020.
    • 12 Dec 2018 Planned primary completion date changed from 1 Oct 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top